Abstract:The main actions of metformin are as follows: To reduce hyperglycemia via the suppression of gluconeogenesis, improve glucose uptake and insulin sensitivity, and stimulate activation of adenosine monophosphate-activated protein kinase during the treatment of diabetes mellitus. It is well known that metformin acts via complex mechanisms, including multitarget and multipathway mechanisms; however, the multi-targeted antidiabetic genes of metformin remain obscure. The present study aimed to perform transcriptomic and proteomic analysis of potential therapeutic target genes in the liver of metformin-treated Sprague-Dawley rats with type 2 diabetes mellitus. The type 2 diabetes rat model was established using streptozotocin. Fasting blood glucose, hemoglobin A1c, serum insulin and biological parameters were subsequently measured. Differentially expressed genes (DEGs) and proteins were identified in the rat livers by expression profile analysis and isobaric tags for relative and absolute quantitation (iTRAQ). A 1.5-fold alteration in gene expression, as determined using chip-based expression profile analysis, and a 1.2-fold alteration in protein expression, as determined using iTRAQ, were considered physiologically significant benchmarks, which were used to identify DEGS in metformin-treated rats with type 2 diabetes mellitus. The DEGs were verified using quantitative polymerase chain reaction (qPCR) and western blot analysis. Numerous hepatic genes involved in various metabolic pathways were affected by metformin; in particular, genes associated with lipid metabolism were markedly affected. Expression profile analysis and iTRAQ analysis suggested that carboxylesterase 1C subunit (Ces1C) and cholesterol 7-hydroxylyase (Cyp7a1) may serve as important DEGs, which were validated by qPCR and western blot analysis. Ces1C and Cyp7a1 are the main enzymes in cholesterol metabolism, yet the result of western blotting was not consistent with qPCR. The present study demonstrated that metformin may affect the expression of numerous hepatic genes involved in metabolic pathways, particularly the lipid and cholesterol metabolic pathways. Ces1C and Cyp7a1 may be considered novel therapeutic target genes in the liver, which are involved in the antidiabetic effects of metformin.

Metformin ameliorates skeletal muscle insulin resistance by inhibiting miR-21 expression in a high-fat dietary rat model

Metformin ameliorates insulin resistance in L6 rat skeletal muscle cells through upregulation of SIRT3

Transcriptomic and Proteomic Analysis of Potential Therapeutic Target Genes in the Liver of Metformin‑treated Sprague‑Dawley Rats with Type 2 Diabetes Mellitus

Metformin ameliorates PA-induced skeletal muscle insulin resistance by suppressing SREBP-1c

Metformin Suppresses Lipid Accumulation in Skeletal Muscle by Promoting Fatty Acid Oxidation.

The role of ZEB1 in mediating the protective effects of metformin on skeletal muscle atrophy

MiRNA-21 Mediates the Antiangiogenic Activity of Metformin Through Targeting PTEN and SMAD7 Expression and PI3K/AKT Pathway

Metformin Ameliorates High Uric Acid-Induced Insulin Resistance in Skeletal Muscle Cells.

Metformin Preserves Insulin Secretion in Pancreatic Β-Cells Through FGF21/Akt Pathway in Vitro and in Vivo.

Effect of metformin on SFRP5 release and insulin resistance in diabetic rat

Maternal Metformin Treatment during Gestation and Lactation Improves Skeletal Muscle Development in Offspring of Rat Dams Fed High-Fat Diet

Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21

Metformin Attenuates Palmitic Acid-Induced Insulin Resistance In L6 Cells Through The Amp-Activated Protein Kinase/Sterol Regulatory Element-Binding Protein-1c Pathway

Dihydromyricetin improves skeletal muscle insulin resistance by inducing autophagy via the AMPK signaling pathway

Influence of metformin on the protein expression of IRS-1 in target tissues of OLETF rats

Effect of Metformin-Induced Stimulation on the Expression of Insulin Receptor Substrate 1 Through Negative Regulation of P70S6k

Metformin increases tauroursodeoxycholic acid levels to improve insulin resistance in diet-induced obese mice

Metformin Ameliorates Hepatic Steatosis and Inflammation Without Altering Adipose Phenotype in Diet-Induced Obesity.

Metformin Alleviates HFD-induced Oxidative Stress in Hepatocyte Via Activating SIRT6/PGC-1α/ENDOG Signaling

Metformin Alleviates Steatohepatitis in Diet-Induced Obese Mice in a SIRT1-Dependent Way

Metformin prevents LYRM1-induced insulin resistance in 3T3-L1 adipocytes via a mitochondrial-dependent mechanism.